Could your own blood cells tame MS? early trial shows promise

NCT ID NCT06430671

Completed Disease control Sponsor: Cellerys AG Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a new treatment for relapsing-remitting multiple sclerosis (RRMS) that uses a patient's own red blood cells. The cells are coated with specific peptides and given back to the patient to teach the immune system to stop attacking the body. The study involved 11 adults with RRMS and focused on safety, not yet on curing the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)

Contacts and locations

Locations

Azienda Ospedaliero Universitaria Careggi

Florence, Tuscany, 50134, Italy
Bellevue Medical Group (BMG), Neurozentrum

Zurich, 8001, Switzerland
Fraunhofer Institut für Translationale Medizin und Pharmakologie (ITMP)

Göttingen, Lower Saxony, 37075, Germany
Neurologická klinika 2. LF UK a FN Motol

Prague, 15006, Czechia
RS Centrum - Neurologická klinika

Prague, 12808, Czechia
UniversitätsSpital Zürich (USZ), Klinik für Neurologie

Zurich, 8091, Switzerland
Universitätsklinikum Hamburg-Eppendorf (UKE), Klinik für Neurologie

Hamburg, 20246, Germany
Universitätsklinikum Münster (UKM), Klinik für Neurologie

Münster, North Rhine-Westphalia, 48149, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.